Findings on Internal Medicine Reported by Investigators at University of Tokyo (An Evaluation of Clinical Economics and Cases of Cost-effectiveness)
By a
Our news editors obtained a quote from the research from the
According to the news editors, the research concluded: "In addition, there is research indicating the superior cost-effectiveness of Rituximab against refractory nephrotic syndrome, and it is expected that health economics will be actively applied to the valuation of technical innovations such as drug discovery."
For more information on this research see: An Evaluation of Clinical Economics and Cases of Cost-effectiveness. Internal Medicine, 2018;57(9):1191-1200. Internal Medicine can be contacted at: Japan Soc Internal Medicine, 34-3 3-Chome Hongo Bunkyo-Ku,
The news editors report that additional information may be obtained by contacting T. Takura,
The direct object identifier (DOI) for that additional information is: https://doi.org/10.2169/internalmedicine.9835-17. This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.
Keywords for this news article include:
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2018, NewsRx LLC
School Board candidates answer questions
Findings on Healthcare Economics Reported by Investigators at Case Western Reserve University (Can financial incentives help people trying to…
Advisor News
Annuity News
Health/Employee Benefits News
Life Insurance News